Publication:
Compassionate use of remdesivir in children with COVID-19.

dc.contributor.authorMendez-Echevarria, Ana
dc.contributor.authorPerez-Martinez, Antonio
dc.contributor.authorGonzalez-Del-Valle, Luis
dc.contributor.authorAra, Maria Fatima
dc.contributor.authorMelendo, Susana
dc.contributor.authorRuiz-de-Valbuena, Marta
dc.contributor.authorVazquez-Martinez, Jose Luis
dc.contributor.authorMorales-Martinez, Antonio
dc.contributor.authorRemesal, Agustin
dc.contributor.authorSandor-Bajusz, Kinga Amalia
dc.contributor.authorCabañas, Fernando
dc.contributor.authorCalvo, Cristina
dc.date.accessioned2023-02-09T10:37:29Z
dc.date.available2023-02-09T10:37:29Z
dc.date.issued2020-11-16
dc.description.abstractChildren represent a minority of total COVID-19 cases, but studies have reported severe disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in children.A nationwide multicenter observational study was conducted on children with confirmed SARS-CoV-2 receiving compassionate treatment with RDV in Spain. Eight patients were included in the study, four infants and four older children [median age 5 years old; IQR 4 months-11.6 years old]. Half of them had complex underlying medical conditions, and the rest were mostly infants (3/4). Six out of eight children needed Pediatric Intensive Care Unit Admission. No RDV-related adverse outcomes were observed in our patients. Seven have reached successful clinical outcome, but one patient with serious clinical status died due to complications. However, she received RDV very late after the first COVID-19 symptom.Conclusions: In our cohort, most of the patients achieved successful clinical outcome, without observing adverse events. Clinical trials of RDV therapy for children with COVID-19 are urgently needed, to assess the safety, tolerability, efficacy, and pharmacokinetics of RDV in children, as this could be an effective treatment in severe cases. What is Known: • Remdesivir has not been approved to treat COVID-19 in children under 12 years old, although the drug is currently being prescribed in critically ill children. • Remdesivir has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in paediatric population. What is New: • We report a multicentre cohort of children with confirmed SARS-CoV-2 and severe COVID-19 disease receiving remdesivir during the first month of the pandemic in Spain. • No remdesivir-related adverse outcomes were observed in most of the cases. Seven patients reached successful clinical outcome, and one died due to complications (bacterial sepsis).
dc.description.versionSi
dc.identifier.citationMéndez-Echevarría A, Pérez-Martínez A, Gonzalez Del Valle L, Ara MF, Melendo S, Ruiz de Valbuena M, et al. Compassionate use of remdesivir in children with COVID-19. Eur J Pediatr. 2021 Apr;180(4):1317-1322
dc.identifier.doi10.1007/s00431-020-03876-1
dc.identifier.essn1432-1076
dc.identifier.pmcPMC7668659
dc.identifier.pmid33200304
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668659/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s00431-020-03876-1.pdf
dc.identifier.urihttp://hdl.handle.net/10668/16616
dc.issue.number4
dc.journal.titleEuropean journal of pediatrics
dc.journal.titleabbreviationEur J Pediatr
dc.language.isoen
dc.organizationHospital Universitario Regional de Málaga
dc.page.number1317-1322
dc.provenanceRealizada la curación de contenido 19/03/2025
dc.publisherSpringer
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
dc.rights.accessRightsRestricted Access
dc.subjectCOVID-19
dc.subjectChildren
dc.subjectInfant
dc.subjectRemdesivir
dc.subjectSARS-CoV-2
dc.subject.decsSARS-CoV-2
dc.subject.decsInforme de Investigación
dc.subject.decsUnidades de Cuidado Intensivo Pediátrico
dc.subject.decsFarmacocinética
dc.subject.decsSepsis
dc.subject.decsPandemias
dc.subject.meshAdenosine Monophosphate
dc.subject.meshAdolescent
dc.subject.meshAlanine
dc.subject.meshAntiviral Agents
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshCompassionate Use Trials
dc.subject.meshCritical Illness
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshMale
dc.subject.meshSeverity of Illness Index
dc.subject.meshSpain
dc.subject.meshTreatment Outcome
dc.subject.meshCOVID-19 Drug Treatment
dc.titleCompassionate use of remdesivir in children with COVID-19.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number180
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format